As previously reported, Jefferies analyst David Stanton upgraded Mesoblast to Buy from Hold with a price target of A$3.30, up from A$3. Ryoncil continues to be rolled out and the firm forecasts 78 patients will complete therapy in FY26, up from 63, while updating its estimates for fiscal Q2 results and FY26 forecasts.
